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Summary 
Using a selection process designed to reflect clinically relevant conditions, a 
panel of taxane-selected variants were developed to study further the 
mechanisms of resistance in lung cancer.  Unlike continuous or pulse 
exposure to high concentrations of chemotherapeutic drugs which yield high 
resistance and often cross resistance, most variants developed here 
displayed low level resistance to the selecting drug with slight cross-
resistance.  Pulsing with taxol resulted in more highly resistant clones (up to 
51.4-fold).  Analysis of taxol and taxotere in the four major lung cancer cell 
types showed the taxanes to be more effective against NSCLC (with the 
exception of SKMES-taxane selected variants) than against the SCLC.  
Comparison of taxol and taxotere shows that taxol induces higher levels of 
resistance than taxotere.  Further, in taxotere-selected cell lines, the cells are 
more resistant to taxol than taxotere, suggesting that taxotere may be a 
superior taxane from a clinical view.  Taxol treatment resulted in increased 
cross-resistance to 5-FU in all classes of lung cancer except DMS-53.  The 
high levels of Pgp in the DMS-53 and selected variant suggests this 
mechanism is not related to Pgp expression.  Analysis of the Pgp and MRP-
1 status by combination inhibitory assays and Western blotting showed no 
consistent relationship between expression of the membrane pumps Pgp or 
MRP-1 and resistance.  However, where high level resistance was seen, the 
parent cell line expressed Pgp or MRP-1 and was accompanied by increased 
levels in the variants.  
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Abbreviations: SCLC = Small Cell Lung Cancer; LCLC = Large Cell Lung 
Cancer; NSCLC = Non-small Cell Lung Cancer; H1299 = NCI-H1299; 
H460 = NCI-H460; FCS= foetal calf serum; Pgp = P-glycoprotein; MRP = 
MDR related protein; 5-FU = 5-fluorouracil; VP-16 = etoposide. 
 
Introduction 
Lung cancer is the most lethal cancer worldwide with 1.5 million cases 
diagnosed in 2003 [1] exceeding those from breast, colon and prostate 
combined [2].  Causes of lung cancer include smoking (about 87%), 
exposure to chemicals such as asbestos and arsenic, as well as the naturally 
occurring radioactive gas radon [3].   Despite being one of the easiest 
cancers to prevent, it remains one of the most difficult to cure, due to the 
late stage of presentation, the presence of metastasis and the development of 
chemotherapy resistance. 
As surgery is only curative in early stage lung cancer, radiation and 
chemotherapy are the alternative treatments.  The chemotherapeutic drugs 
used depend upon which classification the cancer belongs to, namely small 
cell lung cancer (SCLC) or non-small cell lung cancer (NSCLC).  NSCLC 
patients are traditionally treated with cisplatin, carboplatin, VP-16, 
vinblastine, vindesine and more recently taxol, taxotere, irinotecan, 
vinorelbine and gemcitabine [2].  In the treatment of SCLC, primarily 
cisplatin, carboplatin VP-16, cyclophosphamide, adriamycin, vincristine, 
and ifosfamide are used [4].  The most commonly used combination in the 
treatment of SCLC is etoposide and cisplatin. 
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The development of resistance to a particular or a variety of unrelated 
chemotherapeutic drugs (multiple drug resistance, MDR) is a major obstacle 
in the treatment of cancer.  Drug resistance is caused by a variety of changes 
in the cancer cells, for example the increased activity of drug pumps (Pgp 
and MRP family), up or down regulation of topoisomerase or glutathion 
activities and changes in the apoptotic pathways [5,6].   
SCLC representing 20% of all lung cancers have the poorest prognosis, 
being very aggressive and generally present with distant metastases at 
diagnosis [4].  SCLC initially responds to chemotherapy but acquires 
resistance.  NSCLC includes squamous cell carcinoma (30%), 
adenocarcinoma (40%) and large cell carcinoma (10%) often shows intrinsic 
multidrug resistance [7].  The emergence of taxanes as a treatment for lung 
cancer represents significant progress showing substantial activity and a 
unique mechanism of action.  Taxanes are versatile as they are active as a 
single agent or in combination (especially platinum derivatives) and have 
shown to have radiosensitising activity [8]. 
While many studies on lung cancer and resistance have been carried out, 
resistant variants developed from these previous studies were derived using 
drug levels not pharmacologically achievable and the drug administration 
regime did not reflect the clinical setting [9].  In this study, we focused on 
the development of drug resistance in lung cancer across a panel of 
chemotherapy naïve cell lines with taxol or taxotere.   Pulse selection with 
low levels of chemotherapeutic drugs was used to develop resistant variants 
that would reflect the clinical setting. 
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Materials and Methods  
All chemicals (unless otherwise stated), FBS, glutamine and Sulindac were 
obtained from Sigma (Poole, UK).  Cell culture media was supplied by 
Gibco BRL (Paisley, UK).  Adriamycin and carboplatin were obtained from 
EBEWE arzneimittel Ges. m.b.h. (Austria).  Vincristine and cisplatin were 
obtained from Mayne Pharma Plc, (Warwickshire, UK).  VP-16 and taxol 
were obtained from Bristol-Myers Squibb (Dublin, Ireland).  Taxotere was 
obtained from Aventis Pharmaceuticals (Surrey, UK) and 5-FU was 
obtained from Faulding Pharmaceuticals (Warwickshire, UK).  GF120918 
was obtained from GlaxoSmithKline (Middlesex, UK).  Primary and 
secondary antibodies ß-actin and anti-mouse were obtained from Sigma 
(Poole, UK). Anti-Pgp and anti-MRP-1 antibodies were obtained from Santa 
Cruz (California, USA). 
 
Cell lines 
The adenocarcinomas (A549 and SKLU1), large cell lung cancer (NCI-
H1299 and NCI-H460) and the squamous cell lung carcinoma SKMES1, 
were obtained from the ATCC (Bethseda MD). The small cell lung cancer 
DMS-53 was obtained from the European collection of cell culture.  The 
poorly differentiated squamous cell lung carcinoma DLRP, was developed 
in our centre [10].  DMS-53 and variants were grown in RPMI 1640 with 
10% FBS, 1% NEAA, sodium pyruvate and L-glutamine while H460, 
H1299 and variants were supplemented with 5% FBS.   DLRP, A549 and 
variants were grown in ATCC with 5% FBS and L-glutamine.  SKLU1, 
SKMES1 and variants were grown in MEM with 1% NEAA, sodium 
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pyruvate and L-glutamine and 5% or 10% FBS respectively.  All taxol-
selected variants were referred to as –txl e.g. A549-txl and taxotere-selected 
variants were referred to as –txt e.g. SKMES1-txt. 
 
Toxicity testing 
Toxicity was assessed in 96-well plates with acid phosphatase activity as the 
end point [11].  Cells were set up in growth medium at 1x103 per well and 
allowed to incubate overnight at 5% CO2 and 37oC.  Cytotoxic drug 
dilutions were prepared freshly at 2X final concentration and an equivolume 
added to each well.  The plates were incubated for a further 6 or 7 days until 
confluency was being approached in the control cells before assessment of 
cell survival.  The concentration of drug causing 50% kill (IC50 of the drug) 
was determined from a plot of % survival versus cytotoxic drug 
concentration. 
 
Combination assays 
Cells were set up as for Toxicity assays.  After overnight incubation, 
cytotoxic drug dilutions and inhibitors were prepared at 4X final 
concentration.  Volumes of 50μl drug dilution and 50μl inhibitor were added 
to cells to a final 1X concentration and allowed to incubate for 6 – 7 days at 
5% CO2 and 37oC until confluency was being approached in the control 
cells. Toxicity was assessed in 96-well plates with acid phosphatase activity 
as the end point [11].    
 
Pulse selection of parent cell lines 
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Parent cell lines were pulsed with taxol or taxxotere.  SKMES1 and DMS-
53 were pulsed with taxol (140nM and 70nM respectively) or taxotere 
(74.4nM and 49.6nM respectively).  DLRP was pulsed with taxotere 
(6.2nM).  A549, SKLU1, H1299 and H460 were pulsed taxol (175nM, 
11.7nM, 175nM and 58.3nM respectively).  The cells were pulsed with the 
selecting drug for four hours once a week for a period of 10 weeks.   
 
Western blotting 
Western blotting for detection of Pgp and MRP-1 was performed on cell 
lysates that were centrifuged at 1000rpm to remove nuclear material.  
Protein determination was made using the Biorad method.  Samples were 
separated on a 10% SDS gel [12] with 20g loaded per well.  After Western 
blotting [13], blots with primary antibodies (Santa Cruz Biotechnology) 
were incubated overnight at 4C.  Secondary antibody conjugated to horse-
radish peroxidase (Sigma) were detected by enhanced chemiluminesence 
(ECL, Amersham).  Positive controls were used for each antibody.   
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Results  
Toxicity profile of lung cancer cells to selecting drugs 
In order to study trends in lung cancer resistance, a panel of cell lines 
encompassing the 4 main types (adenocarcinoma; large cell lung carcinoma; 
squamous lung carcinoma and small cell lung carcinoma) were chosen on 
the basis of no previous exposure to chemotherapeutic drugs, and were 
exposed to taxol or taxotere. 
Toxicity profiles to taxol and taxotere (Figure 1) show considerable 
differences in the sensitivity of the parent cell lines.  Adenocarcinomas 
(A549 and SKLU1) exhibit a lower IC50 to taxol than LCLC (H1299 and 
H460), 1.3nM as compared to 4.8nM respectively on average.  Sensitivity to 
taxol in the squamous cell lines (SKMES1 and DLRP) was not as consistent 
with DLRP (10.45nM IC50) being 7.5-fold more resistant to taxol than 
SKMES1 (1.4nM IC50).  The SCLC, DMS-53 was most resistant to taxol. 
Taxotere, the other taxane used in these studies, did not show the same 
profile as taxol.  In NSCLC, the IC50 for taxotere was consistently low 
(about 1nM) whereas the SCLC cell line DMS-53 has a high innate 
resistance to taxotere with the IC50 being 10-fold higher than the other cell 
lines in the panel.  DLRP and both LCLC are very sensitive to taxotere but 
not taxol. 
 
The resistance of the parental cell lines to a variety of other 
chemotherapeutic drugs was also assessed (Table I).  Across all the parent 
cell lines, the taxanes (shown in Figure 1) are the most effective on a molar 
basis with the next being vincristine and then adriamycin, with IC50s 
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ranging 18nM – 71nM and 2nM – 28nM respectively, while the platinum 
drugs (carboplatin and cisplatin) and 5-FU are active at micromolar 
concentrations.  For adriamycin, the high IC50 in DLRP correlates to the 
high innate resistance to taxol but no such correlation is seen with DMS-53.  
For vincristine, the pattern of resistance follows a similar trend to that of 
taxotere with all the other cell lines having similar IC50 values of 11nM- 
13nM (except SKLU1 at 2.4nM), while DMS-53 is twice as resistant.  The 
panel was least resistant to cisplatin and 5-FU.  Cisplatin, like carboplatin 
was more effective against DMS-53 (IC50 0.4μM – 0.5μM) than NSCLC 
(0.7μM – 2.2μM) but was more toxic to the cells than carboplatin.  The 
effect of 5-FU was quite variable in all the subtypes except LCLC (1.3μM).  
SKLU1, DLRP and to a lesser extent DMS-53, were less sensitive to 5-FU.  
For VP-16, DLRP and DMS-53 displayed greater than 2-fold higher 
resistance than the other cell lines, with IC50s of 0.74μM and 0.48µM 
respectively.   
 
The panel of cell lines was pulsed with a taxane (taxol or taxotere) to 
generate a number of drug-resistant variants to investigate what happens to 
the innate resistance of these cell lines.  The cells were pulsed with or near 
to pharmacologically achievable levels for 4 hour intervals over a 10 week 
period to closely reflect the clinical scenario [8]. The changes in IC50 after 
pulsing are shown in Figure 2. All the cell lines except DLRP were pulsed 
with taxol.  Taxol-selected variants resulted in a moderate increase in 
resistance for the adenocarcinomas and LCLC with IC50s ranging from 7nM 
to 20nM, corresponding to 2.5-fold to 5.5-fold increases relevant to the 
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parent.   SKMES1-txl displayed high resistance to taxol with an IC50 of 
57.5nM, corresponding to a 24.7-fold increase compared to parent. DMS-53 
variants selected with taxol displayed the highest IC50 values of all the 
variants developed for this work at 94.5nM, corresponding to 6.3-fold 
relative to the parent.  The DMS-53 parent displayed the highest intrinsic 
resistance to taxol of the panel. 
Three of the cell lines were selected with taxotere.  The greatest change in 
resistance was seen in SKMES1, with the IC50 increasing from 0.9nM to 
25nM, but this was unstable and started to decrease with time. At the 
highest IC50, this cell line displayed a 29.1-fold increase compared to parent. 
The increased resistance in DLRP was a modest 4.1-fold (IC50 of 3.8nM) 
while for DMS-53 with high innate resistance, only a 1.8-fold increase in 
resistance is observed.   
 
Cross resistance profile to chemotherapeutic drugs in selected variants 
Each of the pulse-selected drug variants were screened with a panel of 
chemotherapeutic drugs to look at the cross-resistance profile (Figure 3). 
Modest cross-resistance was observed to adriamycin in most of the cell lines 
ranging from 1.3 to 7.5-fold. The LCLC variants showed no change in 
response to adriamycin compared to parental cells. The SKMES1 taxol- and 
taxotere- selected variants showed a dramatic cross-resistance to 5-FU (10-
fold and 13.2-fold) which was not observed in any of the other cell lines. No 
major cross-resistance developed to the platinum agents cisplatin and 
carboplatin in any of the variants with the largest changes observed in 
H1299-txl of 1.5-fold increase in resistance to cisplatin and 1.7-fold 
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increase in resistance to carboplatin. Some of the variants, however, 
developed increase sensitivity to the platinum agents, especially to 
carboplatin (H460-txl, SKMES1-txl and SKMES1-txt).  Cross-resistance to 
VP-16 was observed in A549-txl (4.2-fold), SKMES1-txl (9.2-fold), 
SKMES1-txt (3.9-fold) and DLRP-txt (3.6-fold).  Across all the 
chemotherapeutic agents tested the most cross-resistance was displayed 
against vincristine with SKMES1-txl and SKMES1-txt showing 24.4-fold 
and 19.6-fold resistance respectively. The other variants showed slight 
changes in the range of 1-3.5-fold. 
 
Detection and inhibition of Pgp and MRP-1  
Combination assays with MRP-1 inhibitor sulindac or Pgp inhibitor 
GF120918 were conducted to investigate the involvement of these 
membrane pumps in drug resistance in the panel of cell lines.  Toxicity 
assays were carried with a combination of the non-steroidal anti-
inflammatory drug sulindac with adriamycin or a combination of GF120918 
with taxol.   For each cell line or variant, the percentage cell survival was 
calculated for the drug, the inhibitor and the combination.  Increased cell 
kill in the combination indicates the contribution of either pump to cellular 
resistance.  For instance, in Figure 4a, taxotere at 7.5ng/ml and GF120918 at 
75μg/ml were not inhibitory individually, while the combination causes 
approximately 75% cell kill in SKMES1-txt.  This is slightly more than the 
kill observed in the parent with taxotere at the same concentration, 
suggesting that alterations in the expression of Pgp could almost wholly 
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account for the increased resistance in SKMES1-txt.  Consistent with this, is 
the expression of Pgp in the taxotere-selected variant (Figure 4b).   
A summary of the results observed in all combination assays can be seen in 
Table II. 
Sulindac combination with adriamycin show mixed results across the panel 
of cell lines.  For the adenocarcinomas (A549, SKLU-1), selection with 
taxol did not increase the combination effect from that of the parent (effect 
or none for A549 and SKLU-1 respectively).  For A549 as mentioned 
previously, this may reflect the high basal level of MRP-1 detected in the 
parent.  Western blotting for MRP-1 correlated for A549 and variants with 
no change, however for SKLU-1, both selected variants expressed MRP-1 
while the parent did not.  The combination of GF120918 and taxol showed 
no enhanced effect in any of the adenocarcinomas, correlating with the lack 
of expression of Pgp detected by Western blotting.  In LCLC, no significant 
effect on combination was seen.  The MRP-1 status of these cell lines was 
not consistent.  The H460 parent and selected variants were positive for 
MRP-1, while H1299 and H1299-tax were negative. The combination of 
GF120918 and taxol only showed an enhanced effect in the parent H1299 
and not in the selected variants or any of the H460 cell lines.  However, Pgp 
expression was detected in H1299 and H1299-txl.  
For the squamous lung cancer cell lines, the GF120918/taxotere 
combination showed an effect for SKMES1 but not DLRP parents. DLRP 
showed no effect by combination assay.  For SKMES1, the taxotere-
selected variant was negative for MRP-1 and the carboplatin-selected 
variant was positive.  SKMES1-txt was more effective in this combination 
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and the carboplatin less effective.  Western blots for Pgp similarly show 
increased expression of Pgp in the taxane-selected variants of SKMES1. For 
the SCLC, only the DMS-53 and variants were tested.  While the parent 
showed activity for the sulindac/adriamycin combination, none of the 
variants did.  The GF120918/taxol combination showed increased effect in 
the variants with the taxane- selected variants.  Western blot analysis 
confirmed increased expression of Pgp in the taxane-selected variants. 
 
Changes in in vitro invasiveness 
The invasive abilities of the selected cell lines were compared to parental 
cells (Figure 5).   In three of the cell lines (A549, H1299 and SKMES1) 
taxol selection led to a slight increase in invasiveness. Two of the taxol-
selected variants (SKLU1 and H460) displayed a decrease in invasion 
compared to parent. The two taxotere-selected cell lines tested displayed 
increased invasion. The SCLC cell line DMS53 and its variants were non-
invasive so were not included in these experiments. 
 
Discussion 
The introduction of taxanes in the treatment of lung cancer represented a 
significant progress, being effective alone or in combination (with a 
platinum agent or VP-16) to treat NSCLC and SCLC respectively [14].  A 
downside is the development of drug resistance [15].  Most in vitro studies 
of drug resistance are based on continuous exposure of cells to non-
pharmacologically achievable levels of chemotherapeutic drugs.  These in 
vitro models usually display very high resistance up to 1000-fold, which is 
14 
unlikely to represent resistant tumour cells in situ.  Hence the factors 
causing resistance in highly resistant variants may not reflect those involved 
in clinical resistance. 
In the clinical setting, patients receive chemotherapy treatment once every 
1-3 weeks allowing for recovery in between [8].  By pulsing 
chemotherapeutic naïve cells once weekly for four hours and allowing the 
cells time to recover, resistant variants were developed exhibiting modest 
changes in resistance with some cross resistance.  These variants were 
selected at sustainable pharmacological levels [16].  These variants thus 
provide a suitable model for in vitro investigations into drug resistance.   
Comparison of taxol and taxotere shows differences in resistance despite 
having a similar mechanism of action.  In the present study, resistance to 
taxol was higher than taxotere regardless of whether the selecting drug had 
been taxol or taxotere.  In similar studies in our lab, a taxotere-selected 
squamous lung cancer cell line (DLKP) had IC50s of 166.2nM and 536.7nM 
for taxotere and taxol respectively (unpublished data).  A similar study, [17] 
found taxol-selected ovarian cancer cells KF-tx to be more resistant to taxol 
(IC50 705.3nM) than taxotere (IC50 351nM).  These studies indicate cross-
resistance is present, but the cell lines are not fully cross-resistant as 
suggested by Adroulakis et al[18].  That the fold difference for taxotere in 
taxol-selected variants is greater than taxol suggests that taxol and taxotere 
share some mechanisms of action but also that taxotere through increased 
affinity for microtubules [19] or additional mechanisms exerts greater 
toxicity.  Interestingly, at clinical doses, in KF-tx cells, taxotere induced 
Bcl-2 phosphorylation while taxol did not.  There was also a greater degree 
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of tubulin polymerisation activity on treatment with taxotere than taxol with 
no changes in cell cycle distribution as determined by flow cytometry [17].  
Haldar and colleagues have shown that taxotere is 10- to 100-fold more 
potent at Bcl-2 phosphorylation than taxol [20].   
The cross-resistance profiles show taxol selection increased adriamycin 
resistance in squamous and adenocarcinomas and SCLC but not in LCLC.   
For the adenocarcinomas, the increased resistance in adriamycin and less so 
to vincristine correlate with the presence of MRP-1 found in A549 and 
variants and SKLU1-txl (Figure 3).  Interestingly, there is a 4-fold increase 
in cross-resistance to VP-16 in A549-txl.  That the cross resistance is greater 
than that seen with adriamycin suggests mechanisms other than increased 
MRP-1 may also be active including inhibition of microtubule formation or 
decreased topoisomerase II activity [14].  Taxol-resistant variants of A549 
with 17 and 9-fold resistance to taxol [21] both showed a mutation in the -
tubulin iso-type K1 and low level expression of P-gp in A549-T24 and not 
in A549-T12. 
Resistance to vincristine was high in squamous cell carcinomas, modest in 
LCLC and SCLC and low in adenocarcinomas.  VP-16 cross resistance was 
sporadic.  Cross-resistance to 5-FU was low in all except squamous cell 
carcinomas, although taxol treatment resulted in increased cross-resistance 
to 5-FU in all classes of lung cancer.  The exception was DMS-53, having 
high basal levels of Pgp in the parent and selected variants.  Previous studies 
have shown that Pgp expression dose not correlate with 5-FU cross-
resistance [22]. As resistance to taxol and vincristine decreases, the 
resistance to 5-FU decreases only slightly.  A previous study in our lab on 
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the nasal septum carcinoma cell line RPMI-2650 found that taxol-selected 
variants displayed an increase in cross-resistance to 5-FU that was not 
observered in melphalan-selected variants [23]. 
The increased resistance in taxane-selected variants observed in the present 
study may be due to a number of mechanisms including increased drug 
efflux, alterations in microtubule dynamics, mutations/alterations in tubulin 
[24] and changes in expression of apoptosis-related proteins e.g. caspases 
and the bcl-2 family [25]. While alterations in Pgp expression have been 
linked to clinical resistance in breast cancer cell lines and tumour samples 
[22] and NSCLC [26], the results from Western blotting and combination 
assays on the variants in this work, suggest that other mechanisms are also 
important.  Changes in the ß-tubulin isotypes have been noted in taxol-
resistant variants with low level exposure where no change in MDR1 was 
observed [27].   
From the combination assays here, it can be seen that if a combination of 
GF120918 and taxol show an effect in the parent, it is increased in the 
taxane-resistant variants. Further, no significant effect with GF120918 and 
taxol was observed in Adenocarcinomas or LCLC except for H1299 parent.  
Interestingly, no increase in H1299 resistant variants is seen. In H460 and 
variants, MRP-1 but not Pgp expression is detected whereas in H1299 and 
H1299-txl, the reverse is seen (Table II).  The combination assays however 
show no strong effect on taxol-selected variants in either of the LCLC cell 
lines. 
Pulse-selection with a chemotherapeutic agent has been known to affect 
other functions of the cell, such as proliferation and invasion.  Taxol 
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treatment has been linked to decreased invasion and motility. A study on the 
effect of taxol on the adhesive and motility properties of human ovarian 
carcinoma cell lines, OVCAR 5, SK-OV-3, and HOC-1OTC [28] found that 
taxol significantly inhibited the motility of these cell lines but it did not 
affect their adhesion to the subendothelial matrix. In the present study, 
mixed effects on in vitro invasion were observed with taxol selection. H460-
txl showed a dramatic decrease in invasion in agreement with the above 
study. However taxotere exposure led to a consistent increase in invasion. 
Previous studies in our laboratories have shown that selection with some 
chemotherapeutic agents can lead to increased in vitro invasiveness [23].  
Another study on the invasive breast cancer cell line MDA-MB-435S-F 
found that selection with the agents taxol and adriamycin led to a more 
aggressive invasive phenotype termed “superinvasive” [29].   
 
Conclusion 
In this study, we have found that development of drug-resistant variants 
selected to reflect the clinical scenario, can produce variants with 
mechanisms of resistance different to those seen at high doses and/or 
continuous exposure.  These variants thus provide a suitable in vitro model 
to study clinically relevant resistant mechanisms.   
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Figure legend: 
Figure 1: IC50 values of parent cell lines to taxol and taxotere.   
Cells were exposed to increasing drug concentrations and growth measured 
using the acid phosphatase assay.  The IC50 value for each cell line was 
obtained from a plot of drug concentration versus percentage cell survival.  
Results are expressed as the average of three separate repeats.    
 
Figure 2:  Fold resistance of variants to taxol and taxotere.    
The value for each IC50 was obtained from a plot of drug concentration 
versus percentage cell survival.  Results are expressed as the average of 
three separate repeats. (SKLU1 IC50 values for taxotere were inconsistent 
and were not included). 
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Figure 3: Cross resistance profile of selected variants compared to the 
parental cell lines.   
IC50 values (n=3) for six chemotherapeutic drugs (adriamycin, 5-
fluorouracil, cisplatin, carboplatin, VP-16 and vincristine) were compared in 
the resistant cell lines.  
 
Figure 4:  Combination of taxotere and GF120918 in SKMES1-txt and 
expression of Pgp protein in SKMES1 and SKMES1-txt. 
Graph (a) shows the percentage survival of SKMES1-txt treated with low-
toxicity quantities of taxotere and the Pgp inhibitor GF120918 and the effect 
of the combination of these agents. 
(b) Western blot analysis of Pgp protein expression in SKMES1 and 
SKMES1-txt. Β-actin is included as an endogenous control. 
 
Figure 5: Changes in in vitro invasiveness of taxol- and taxotere- 
selected variants compared to parental cell lines.   
This invasion was quantified by counting the number of invading cells and 
results are expressed as the average of three separate repeats. (n=3). 
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 Adr (nM) Cis (uM) Carbo(μM) 5-FU (uM) VP-16 (uM) Vcr (nM) 
A549 29.41 ± 0.34 1.93 ± 0.11 15.78 ± 0.54 1.16 ± 0.11 0.20 ± 0.03 12.58 ± 1.7 
SKLU1 46.07 ± 0.68 1.34 ± 0.07 7.53 ± 0.64 9.40 ± 0.57 0.20 ± 0.01 2.38 ± 1.02 
H1299 51.51 ± 1.53 1.44 ± 0.09 9.95 ± 1.61 1.17 ± 0.12 0.19 ± 0.02 8.16 ± 0.34 
H460 18.87 ±2.72 0.83 ± 0.10 6.46 ± 0.54 1.45 ± 0.13 0.13 ± 0.01 12.58 ± 2.04 
SKMES1 12.41 ± 0.68 2.22 ± 0.26 12.37 ± 0.54 0.69 ± 0.05 0.10 ± 0.00 12.92  ± 1.02 
DLRP 69.19 ± 5.27 0.74 ± 0.07 9.42 ± 0.97 9.61 ± 1.02 0.74 ± 0.07 11.12 ± 0.71 
DMS-53 25.50 ± 2.89 0.50 ± 0.04 3.23 ± 0.27 5.63 ± 0.44 0.50 ± 0.04 27.78 ± 3.26 
 
Table I: IC50 values of parent cell lines to adriamycin, cisplatin, 
carboplatin, 5-FU, VP-16 or vincristine (Vcr).   
Results are the average of a least three separate experiments. 
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Cell line 
Sulindac and 
adriamycin 
MRP-1 
expression 
GF120918 
and taxol* 
Pgp 
expression 
A549 + Y - N 
A549-tax + Y - N 
SKLU1 - N - N 
SKLU1-tax - Y - N 
H1299 - N + Y 
H1299-tax - N - Y 
H460 - Y - N 
H460-tax - Y - N 
DLRP -  -  
DLRP-txt -  -  
SKMES1 -  ++ Y 
SKMES1-tax -  Nd Y 
SKMES1-txt -  +++ Y 
DMS-53 +  + Y 
DMS-53-tax -  +++ Y 
DMS-53-txt -  +++ Y 
 
Table II: Summary of effects observed in combination assays.  
AC=adenocarcinoma; LCC=large cell carcinoma; SCC=squamous cell 
carcinoma and SCLC=small cell lung carcinoma. + indicates at >20% 
enhanced effect; ++ indicates at >40% enhanced effect; +++ indicates at 
>60% enhanced effect; - indicates no effect; nd=not done. * Indicates that 
taxotere was used in combination assays for SKMES1, DLRP, DMS-53 and 
corresponding variants with GF120918. 
 
 
AC 
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Figure 1: IC50 values of parent cell lines to taxol and taxotere.   
 
Figure 2:  Fold resistance of variants to taxol and taxotere.    
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Figure 3: Cross resistance profile of selected variants compared to the 
parental cell lines.   
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Figure 4:  Combination of taxotere and GF120918 in SKMES1-txt and 
expression of Pgp protein in SKMES1 and SKMES1-txt. 
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Figure 5: Changes in in vitro invasiveness of taxol- and taxotere- 
selected variants compared to parental cell lines.   
 
